Wedbush Comments on Pharvaris’ FY2028 Earnings (NASDAQ:PHVS)

Pharvaris (NASDAQ:PHVS) – Analysts at Wedbush issued their FY2028 EPS estimates for Pharvaris in a research note issued to investors on Thursday, April 11th. Wedbush analyst L. Chico anticipates that the company will post earnings of $1.43 per share for the year. Wedbush currently has a “Outperform” rating and a $35.00 target price on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.15) per share.

PHVS has been the topic of several other research reports. JMP Securities raised their target price on Pharvaris from $49.00 to $50.00 and gave the company a “market outperform” rating in a research report on Thursday, April 11th. Morgan Stanley decreased their price objective on Pharvaris from $35.00 to $34.00 and set an “overweight” rating on the stock in a report on Monday.

Pharvaris Trading Down 8.0 %

PHVS stock opened at $20.15 on Monday. Pharvaris has a 12-month low of $7.93 and a 12-month high of $33.00. The business’s 50-day moving average is $24.77 and its 200 day moving average is $23.30.

Institutional Investors Weigh In On Pharvaris

Large investors have recently made changes to their positions in the stock. venBio Partners LLC boosted its stake in Pharvaris by 15.4% during the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after buying an additional 654,832 shares during the last quarter. Viking Global Investors LP boosted its position in shares of Pharvaris by 13.2% during the 4th quarter. Viking Global Investors LP now owns 3,656,923 shares of the company’s stock valued at $102,577,000 after acquiring an additional 425,000 shares during the last quarter. Novo Holdings A S grew its holdings in shares of Pharvaris by 15.8% in the fourth quarter. Novo Holdings A S now owns 1,539,325 shares of the company’s stock valued at $43,178,000 after purchasing an additional 210,000 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in Pharvaris during the fourth quarter worth about $23,638,000. Finally, Commodore Capital LP purchased a new position in Pharvaris during the fourth quarter worth about $22,440,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).